Rikke Borg

Rikke Borg is a Consultant Clinical Associate Professor at the University of Copenhagen's Faculty of Health and Medical Sciences, Department of Clinical Medicine, specializing in Internal Medicine: Nephrology. She serves as a Specialist in Internal Medicine/Nephrology at Zealand University Hospital Roskilde, maintaining dual academic-clinical appointments since March 1, 2017.

Her research focuses on diabetic kidney disease pathophysiology and management, with particular expertise in $$\text{HbA}_{1\text{c}}$$ and glucose exposure metrics, proteinuria, chronic kidney disease progression, and cardiovascular risk assessment in renal patients. Current work emphasizes translational applications including biomarker validation ($$\text{PRO-C3}$$, $$\text{PRO-C6}$$), electronic health interventions, and precision medicine approaches for diabetic nephropathy.

Recent publications demonstrate leadership in major Danish clinical trials including NUDGE-CKD (electronic nudges for guideline-directed therapy), PRIMETIME cohort (molecular interrogation of diabetic kidney disease), and DANWARD trial (anticoagulation in dialysis patients with atrial fibrillation). Her work integrates epidemiology, registry data analysis, and clinical trial methodology to address gaps in chronic kidney disease management.

Scientific contributions include:

• Development of novel electronic intervention frameworks for chronic disease management
• Advancement of glomerular physiology understanding in diabetic kidney disease
• Validation of serological fibrosis biomarkers for post-COVID complications
• Design of pragmatic trials for anticoagulation in high-risk dialysis populations

Borg maintains active clinical research collaborations across Danish nephrology centers, with significant contributions to national guidelines for chronic kidney disease management in primary care settings through the ATLAS study. Her work bridges clinical practice with translational research through the Steno Diabetes Center Copenhagen network.